HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PRAX
Praxis Precision Medicines, Inc.
There isn't enough reported data to score PRAX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PRAX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
PRAX's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PRAX PE Valuation
PRAX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PRAX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect PRAX's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PRAX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$12.82 | +$0.02 |
| Q2 2026 | -$12.95 | -$0.72 |
| Q1 2026 | -$13.39 | -$2.73 |
| Q4 2025 | -$13.48 | -$3.27 |
| Q3 2023 | -$33.45 | +$43.65 |
| Q2 2023 | -$45.15 | +$32.55 |
| Q1 2023 | -$57.60 | +$13.50 |
| Q4 2022 | -$69.60 | -$10.50 |
PRAX is still losing money, but far less than before: $12.82 per share over the past year, against $77.70 at its worst in mid-2022.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus down 100% for PRAX.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was โ7.4% last quarter, down 9.4 points from the same quarter a year ago.
PRAX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $7.5M | +1349% |
| Q3 2024 | $302K | -35% |
| Q2 2024 | $357K | -54% |
| Q1 2024 | $431K | -37% |
PRAX's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -857% | +4542 points |
| Q3 2024 | -18820% | -13367 points |
| Q2 2024 | -10501% | -6025 points |
| Q1 2024 | -9718% | -4141 points |
| Q4 2023 | -5399% | N/A |
| Q3 2023 | -5452% | N/A |
| Q2 2023 | -4476% | N/A |
| Q1 2023 | -5577% | N/A |
PRAX's operating margin was โ857% last quarter, up 4542 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PRAX on cash generation, producing positive trailing cash flow while its opponent burns cash.
PRAX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$83.3M | -$18.2M |
| Q1 2026 | -$86.2M | -$33.2M |
| Q3 2025 | -$65.1M | -$37.6M |
| Q1 2025 | -$53M | -$32.2M |
| Q3 2024 | -$27.5M | -$4.3M |
| Q2 2024 | -$27.3M | +$3.9M |
| Q1 2024 | -$20.9M | +$12M |
| Q4 2023 | -$23.9M | +$4.9M |
PRAX has burned cash in almost every quarter: โ$324M over the past year, against โ$173M the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PRAX Net Leverage
PRAX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PRAX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.5 | Neutral |
| Stochastic | 38.0 | Neutral |
PRAX's weekly RSI is 54 (neutral) and its Stochastic is 38 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | โ |
HIMS has no meaningful PE right now: it lost money over the past year.
PRAX PE vs Healthcare Sector
PRAX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PRAX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $277.4 | 17% above |
| 20 week MA | $312.2 | 4% above |
| 50 week MA | $309.1 | 5.1% above |
| 100 week MA | $189.4 | 71% above |
| 200 week MA | $113.8 | 185% above |
PRAX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to โ56% in 2021. It's down 42% so far in 2026.
PRAX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $417.0 | $790.1 | +89% |
| 2021 | $790.1 | $309.2 | -61% |
| 2022 | $309.2 | $36.3 | -88% |
| 2023 | $36.3 | $22.3 | -39% |
| 2024 | $22.3 | $77.0 | +246% |
| 2025 | $77.0 | $269.0 | +249% |
| 2026 YTD | $269.0 | $324.8 | +21% |
PRAX has the edge over HIMS on returns for 2026, with the stronger performance.